Prescribing information

 

Support with metaboliser status genotyping prior to MAYZENT initiation.

Once the decision to prescribe MAYZENT is made, but before initiation of MAYZENT, patients must be genotyped for CYP2C9 to determine their CYP2C9 metaboliser status

Table showing CYP2C9 genotypes, their frequencies and suitable dosage of for patients with these genotypes.

MayzentConnect will help you to determine the metaboliser status of your patient and, if appropriate, to proceed and choose the appropriate dose.

We can provide you with:

  • Specific equipment for you to take a patient buccal (cheek) sample
  • The appropriate packaging and postage that is compliant with UK regulations to send the sample to Viapath Analytics LLP
  • Laboratory services to determine the CYP2C9 variation of each patient. The results will be sent back to you within 7 working days, from when Viapath Analytics LLP receive the sample

 

Indication: MAYZENT is indicated for the treatment of adult patients with SPMS with active disease evidenced by relapses or imaging features of inflammatory activity.1

SPMS, secondary progressive multiple sclerosis.

Reference

  1. MAYZENT (siponimod) Summary of Product Characteristics.
     
SIP20-C001f May 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]